Company intelligence / Profile preview
Algernon NeuroScience
Vancouver, British Columbia, Canadaalgernonneuroscience.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Algernon NeuroScience is currently conducting Phase 1 DMT studies and planning Phase 2a trials for stroke treatment. The company has completed dosing subjects in the first cohort of its Phase 1 DMT study in the Netherlands with no safety or tolerability issues reported. A Phase 2a DMT study of 40 stroke patients is expected to begin in Q3 2025 in Hungary.[5][7]
- Therapeutic areas
- Neurology
- Modalities
- Small moleculesPsychedelics
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Validcare (CRO)Netcapital Securities Inc.
Beyond the preview
Go deeper on Algernon NeuroScience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Algernon NeuroScience.